

Khaled Abduljalil

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7528304/khaled-abduljalil-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39
papers

1,106
citations

17
h-index

33
g-index

42
ext. papers

1,333
ext. citations

4.5
avg, IF

4.7
L-index

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 39 | Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 365-96 | 6.2 | 210 |
| 38 | Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults. <i>Biopharmaceutics and Drug Disposition</i> , 2015 , 36, 245-57 | 1.7 | 87 |
| 37 | A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 625-36 | 6.2 | 80 |
| 36 | A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 873-85 | 3.8 | 80 |
| 35 | Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1478-84 | 4 | 71 |
| 34 | Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 207-12 | 5.9 | 58 |
| 33 | Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014 , 3, e124 | 4.5 | 56 |
| 32 | Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. <i>AAPS Journal</i> , 2014 , 16, 568-76 | 3.7 | 55 |
| 31 | Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 88, 643-51 | 6.1 | 43 |
| 30 | Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 103-110 | 4.5 | 37 |
| 29 | Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. <i>Current Drug Metabolism</i> , 2012 , 13, 695-720 | 3.5 | 35 |
| 28 | Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. <i>Frontiers in Pharmacology</i> , 2014 , 5, 258 | 5.6 | 32 |
| 27 | Fetal Physiologically Based Pharmacokinetic Models: Systems Information on the Growth and Composition of Fetal Organs. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 235-262 | 6.2 | 25 |
| 26 | Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1149-1171 | 6.2 | 24 |
| 25 | Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 501-518 | 6.2 | 22 |
| 24 | Considering Age Variation When Coining Drugs as High versus Low Hepatic Extraction Ratio. <i>Drug Metabolism and Disposition</i> , 2016 , 44, 1099-102 | 4 | 21 |
| 23 | A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 485-500 | 6.2 | 18 |

| | | | |
|----|---|-----|----|
| 22 | Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020 , 47, 319-340 | 2.7 | 16 |
| 21 | More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances. <i>Journal of Clinical Pharmacology</i> , 2016 , 56 Suppl 7, S132-42 | 2.9 | 16 |
| 20 | Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 2892-901 | 5.9 | 15 |
| 19 | Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 1352-1361 | 6.1 | 15 |
| 18 | Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents. <i>AAPS Journal</i> , 2020 , 22, 76 | 3.7 | 12 |
| 17 | Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020 , 47, 361-383 | 2.7 | 11 |
| 16 | Fetal Physiologically Based Pharmacokinetic Models: Systems Information on Fetal Blood Components and Binding Proteins. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 629-642 | 6.2 | 9 |
| 15 | Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate. <i>Biopharmaceutics and Drug Disposition</i> , 2018 , 39, 125-134 | 1.7 | 8 |
| 14 | A Tutorial on Pharmacodynamic Scripting Facility in Simcyp. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016 , 5, 455-65 | 4.5 | 7 |
| 13 | Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 521-9 | 2.8 | 6 |
| 12 | Use of a physiologically based pharmacokinetic-pharmacodynamic model for initial dose prediction and escalation during a paediatric clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1378-1389 | 3.8 | 6 |
| 11 | Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 878-889 | 4.5 | 5 |
| 10 | Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 359-71 | 6.2 | 4 |
| 9 | .. <i>Drug Metabolism and Disposition</i> , 2022 , | 4 | 4 |
| 8 | Fetal Physiologically Based Pharmacokinetic Models: Systems Information on Fetal Cardiac Output and Its Distribution to Different Organs during Development. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 741-757 | 6.2 | 4 |
| 7 | Quantification of Fetal Renal Function Using Fetal Urine Production Rate and Its Reflection on the Amniotic and Fetal Creatinine Levels During Pregnancy.. <i>Frontiers in Pediatrics</i> , 2022 , 10, 841495 | 3.4 | 3 |
| 6 | Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach.. <i>Clinical Pharmacokinetics</i> , 2022 , 1 | 6.2 | 2 |
| 5 | Application of Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling in Preterm Neonates to Guide Gentamicin Dosing Decisions and Predict Antibacterial Effect. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 1356-1365 | 2.9 | 2 |

- 4 Authors Reply to Viller et al: "Comment on: Preterm Physiologically Based Pharmacokinetic Model, Part I and Part II". *Clinical Pharmacokinetics*, **2021**, 60, 681-683 6.2 ○
- 3 Application of a Physiologically Based Pharmacokinetic Model to Predict Cefazolin and Cefuroxime Disposition in Obese Pregnant Women Undergoing Caesarean Section. *Pharmaceutics*, **2022**, 14, 1162 6.4 ○
- 2 Physiologically-Based Pharmacokinetics **2011**, 361-386
- 1 Toward Greater Insights on Applications of Modeling and Simulation in Pregnancy. *Current Drug Metabolism*, **2020**, 21, 722-741 3.5